Registration study of early administration of tirofiban in patients treated with intravenous thrombolysis for acute ischemic stroke

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400086525

Enrollment

Unknown

Registered

2024-07-04

Start date

2024-07-07

Completion date

Unknown

Last updated

2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute ischemic stroke

Interventions

Observation group 1 (Intravenous thrombolysis + tirofiban + standard medication):None

Observation group 2 (Intravenous thrombolysis + standard medication):None

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1) Age >18 years old; 2) Acute ischemic stroke according to clinical symptoms or imaging examination; 3) Intravenous thrombolytic therapy has been performed; 4) Written informed consent signed by the patient or family.

Exclusion criteria

Exclusion criteria: 1) Intracranial hemorrhage was confirmed by head CT or MRI; 2) Pre-onset mRS Score = 2; 3) Pregnant or lactating women; 4) Systolic blood pressure >185mmHg or diastolic blood pressure >110mmHg, and antihypertensive drugs can not control; 5) Cardiogenic stroke or potential cardiogenic thrombosis, with any of the following definite causes of cardiac embolism: chronic or paroxysmal atrial fibrillation, mitral stenosis, mechanical valves, endocarditis, intracardiac thrombosis or implants, dilated cardiomyopathy, left atrial spontaneous acoustic imaging; 6) Genetics or acquired bleeding constitution, lack of anticoagulation factors; Or have used anticoagulants and INR>1.7; 7) Blood glucose 22.2mmol, platelet 220umol/L); 10) Life expectancy of <6 months due to the advanced stage of any disease; 11) The follow-up is not expected to be completed; 12) Intracranial aneurysm, arteriovenous malformation; 13) Intracranial space-occupying lesions; 14) Allergic to Tirofiban and contrast agents; 15) Participating in other clinical trials.

Design outcomes

Primary

Measure	Time frame
90-day mRS Score;90-day mortality rate;The incidence of symptomatic intracranial hemorrhage within 72 hours;	—

Secondary

Measure	Time frame
Incidence of intracranial hemorrhage;Incidence of systemic bleeding;	—

Countries

China

Contacts

Public ContactKong Deyan

The Second Affiliated Hospital of Guangxi Medical University

kongdeyangxnn@163.com+86 183 7663 5080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026